Home > Protocol Summaries: Compounds > GSK163090 Protocol Summaries: GSK163090 GSKStudy ID Phase Title Status 103268 Phase 1 An open label, randomised, single dose, three-way crossover study to investigate the relative bioavailability of two different formulations of GSK163090 and the effect of food on the pharmacokinetics of a tablet formulation in healthy male and female volunteers Completed 109035 phase 2 A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of GSK163090 in Subjects with Major Depressive Disorder Completed HTP103265 phase 1 An open label, non-randomized positron emission tomography study in healthy male subjects to investigate brain 5-HT1A receptor occupancy, pharmacokinetics and safety of single oral doses of GSK163090, using the ligand [11C]-WAY100635. Completed HTP110333 Phase 1 A randomized, single-blind, placebo-controlled, 2 part study to evaluate the safety and tolerability of GSK163090 at single and repeat doses in subjects with MDD Completed
